Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$60.2M
52M shares
52-week range
$0.69 – $1.57
54% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
P/S (TTM)
87611
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
www.talphera.comNo one on the platform currently holds TLPH.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 237,755 | $177.6K |
No one on the platform has traded TLPH yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | -65.1% | |||||
| Profit Margin % | -51035.7% | |||||
| Free Cash Flow Margin % | -40585.7% | |||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$TLPH My last order for 5K shares at $1.16 finally went through. Only 14 lots this time. I'm done buying and hope we rise soon The closer we get to the end of the year, it seems like it has to go back up to at least $1.50. I'll keep dreaming of a $3 or $4 buyout next year.
View on StockTwits ↗
$TLPH In weird news today, I placed an order for 5K shares which filled in lots of 3 shares. I ended up with over 1000 alerts on my etrade account. I must have been trading with some type of algo program.
View on StockTwits ↗
$TLPH Shakil Aslam Chief Medical Officer, Talphera Yeah. In terms of the primary endpoint, I can say with a lot of confidence there is essentially no risk to the study. That's very, I would say, daring statement to make, and I'll tell you why. It's not a clinical endpoint per se. We're looking at activated clotting time, which is a measure of how long it takes for blood to clot. All anticoagulants, they work by slowing down the process, so it takes longer for blood to clot. That's very objective. You take a patient whose clotting time is less than 150 seconds, you give them a blood thinner, which is supposed to prolong their clotting time.
View on StockTwits ↗$TLPH "We are obviously over 75% enrolled, so that's great...The changes that we implemented, and we had all the target profile sites up and running, and we have seen tremendous improvement and progress over past few months in terms of enrollment where we are. I think everything right now is going as planned. I feel very confident that we'll wrap this thing up before the end of the year...Shakil Aslam Chief Medical Officer, Talphera Yeah. In terms of the primary endpoint, I can say with a lot of confidence there is essentially no risk to the study. That's very, I would say, daring statement to make, and I'll tell you why. It's not a clinical endpoint per se. We're looking at activated clotting time, which is a measure of how long it takes for blood to clot. All anticoagulants, they work by slowing down the process, so it takes longer for blood to clot. That's very objective. You take a patient whose clotting time is less than 150 seconds, you give them a blood thinner
View on StockTwits ↗
$CRMD $TLPH https://stockanalysis.com/stocks/tlph/transcripts/745443-h-c-wainwright-28th-annual-global-investment-conference/
View on StockTwits ↗$TLPH anybody heard the answer when they asked about cormedix deal?
View on StockTwits ↗$TLPH It's been almost 5 weeks since the last update. With any luck, that should translate into 4 more enrollees, bringing the total to 57. That leaves only 13 more patients to complete the study. In the words of Frankie Valli, "So close, so close and yet so far." Fingers crossed for good news.
View on StockTwits ↗$CRMD $TLPH Just a reminder about Monday investor call…
View on StockTwits ↗$TLPH Still holding strong even on down days for other bio stocks. If we can stay around $1.20 into October, it should be up from there.
View on StockTwits ↗
$TLPH https://ir.talphera.com/news-releases/news-release-details/talphera-participate-hc-wainwright-28th-annual-global-investment
View on StockTwits ↗
Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $4M | +14533.3% | $-0.20 | $-0.28–$-0.13 | — | 2 |
| 2027 | $596000 | -84.9% | $-0.21 | $-0.29–$-0.13 | — | 2 |
| 2028 | $14M | +2203.6% | $-0.13 | $-0.18–$-0.07 | — | 4 |
| 2029 | $37M | +170.2% | $0.06 | $0.04–$0.08 | 19.3× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-13 | $-0.06 | $-0.06 | +4.0% |
| 2026-05-13 | $-0.07 | $-0.04 | +42.9% |
| 2026-03-23 | $-0.07 | $-0.06 | +20.0% |
| 2025-11-12 | $-0.07 | $-0.11 | -46.7% |
| 2025-08-14 | $-0.12 | $-0.10 | +16.7% |
| 2025-05-14 | $-0.17 | $-0.10 | +41.2% |
| 2025-03-31 | $-0.21 | $-0.07 | +66.7% |
| 2024-11-13 | $-0.20 |
| $-0.13 |
| +35.0% |
| $11M |
| — |
| ITRMIterum Therapeutics plc | $0.03 | -10.98% | $2M | — |
| MIRAMIRA Pharmaceuticals, Inc. | $0.83 | +9.61% | $35M | — |
Source: Financial Modeling Prep · peers by sector/industry